Jeniel E Nett

List of Publications by Year
in descending order

78 papers	7,750 citations	61984 43 h-index	76900 74 g-index
82 all docs	82 docs citations	82 times ranked	5939 citing authors

#	Article	IF	Citations
1	Ex Vivo Human and Porcine Skin Effectively Model<i>Candida auris</i>Colonization, Differentiating Robust and Poor Fungal Colonizers. Journal of Infectious Diseases, 2022, 225, 1791-1795.	4.0	14
2	Examining Neutrophilâ€"Candida auris Interactions with Human Neutrophils Ex Vivo. Methods in Molecular Biology, 2022, , 243-250.	0.9	2
3	Priority effects dictate community structure and alter virulence of fungal-bacterial biofilms. ISME Journal, 2021, 15, 2012-2027.	9.8	34
4	Candida auris Cell Wall Mannosylation Contributes to Neutrophil Evasion through Pathways Divergent from Candida albicans and Candida glabrata. MSphere, 2021, 6, e0040621.	2.9	23
5	Editorial: Fungal Biofilms in Infection and Disease. Frontiers in Cellular and Infection Microbiology, 2021, 11, 753650.	3.9	2
6	Augmenting the Activity of Chlorhexidine for Decolonization of Candida auris from Porcine skin. Journal of Fungi (Basel, Switzerland), 2021, 7, 804.	3.5	16
7	Coordination of fungal biofilm development by extracellular vesicle cargo. Nature Communications, 2021, 12, 6235.	12.8	42
8	How Biofilm Growth Affects Candida-Host Interactions. Frontiers in Microbiology, 2020, 11, 1437.	3.5	42
9	Candida auris Infection and Biofilm Formation: Going Beyond the Surface. Current Clinical Microbiology Reports, 2020, 7, 51-56.	3.4	53
10	Lipo-chitooligosaccharides as regulatory signals of fungal growth and development. Nature Communications, 2020, 11, 3897.	12.8	65
11	Neutrophils From Patients With Invasive Candidiasis Are Inhibited by Candida albicans Biofilms. Frontiers in Immunology, 2020, 11, 587956.	4.8	7
12	Spleen Tyrosine Kinase Is a Critical Regulator of Neutrophil Responses to<i>Candida</i>Species. MBio, 2020, 11, .	4.1	25
13	Contributions of the Biofilm Matrix to Candida Pathogenesis. Journal of Fungi (Basel, Switzerland), 2020, 6, 21.	3.5	58
14	Candida auris Forms High-Burden Biofilms in Skin Niche Conditions and on Porcine Skin. MSphere, 2020, 5, .	2.9	80
15	Exploiting the vulnerable active site of a copper-only superoxide dismutase to disrupt fungal pathogenesis. Journal of Biological Chemistry, 2019, 294, 2700-5412.	3.4	15
16	Insight into Neutrophil Extracellular Traps through Systematic Evaluation of Citrullination and Peptidylarginine Deiminases. Journal of Immunology Research, 2019, 2019, 1-11.	2.2	50
17	Candida auris: An emerging pathogen â€œincognitoâ€?. PLoS Pathogens, 2019, 15, e1007638.	4.7	47
18	2889. Skin Niche Conditions Trigger C. auris to Form Robust Biofilms That Resist Desiccation. Open Forum Infectious Diseases, 2019, 6, S78-S78.	0.9	0

#	Article	IF	Citations
19	Conserved Role for Biofilm Matrix Polysaccharides in <i>Candida auris</i> Drug Resistance. MSphere, 2019, 4, .	2.9	81
20	Neutrophil extracellular traps in fungal infection. Seminars in Cell and Developmental Biology, 2019, 89, 47-57.	5.0	76
21	Conservation and Divergence in the <i>Candida</i> Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control. MBio, 2018, 9, .	4.1	52
22	970. Emerging Pathogen Candida auris Evades Neutrophil Attack. Open Forum Infectious Diseases, 2018, 5, S37-S37.	0.9	0
23	An unappreciated role for neutrophil-DC hybrids in immunity to invasive fungal infections. PLoS Pathogens, 2018, 14, e1007073.	4.7	49
24	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell, 2018, 5, 300-326.	3.2	81
25	Echinocandin Treatment of Candida albicans Biofilms Enhances Neutrophil Extracellular Trap Formation. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	12
26	Emerging Fungal Pathogen Candida auris Evades Neutrophil Attack. MBio, 2018, 9, .	4.1	89
27	Peptidylarginine deiminase 2 is required for tumor necrosis factor alpha-induced citrullination and arthritis, but not neutrophil extracellular trap formation. Journal of Autoimmunity, 2017, 80, 39-47.	6.5	87
28	The Role of Biofilm Matrix in Mediating Antifungal Resistance. , 2017, , 369-384.		2
29	Blastomyces dermatitidisserine protease dipeptidyl peptidase IVA (DppIVA) cleaves ELR+CXC chemokines altering their effects on neutrophils. Cellular Microbiology, 2017, 19, e12741.	2.1	8
30	Mechanisms involved in the triggering of neutrophil extracellular traps (NETs) by Candida glabrata during planktonic and biofilm growth. Scientific Reports, 2017, 7, 13065.	3.3	51
31	Conserved Inhibition of Neutrophil Extracellular Trap Release by Clinical Candida albicans Biofilms. Journal of Fungi (Basel, Switzerland), 2017, 3, 49.	3.5	30
32	Candida albicans FRE8 encodes a member of the NADPH oxidase family that produces a burst of ROS during fungal morphogenesis. PLoS Pathogens, 2017, 13, e1006763.	4.7	57
33	The Interface between Fungal Biofilms and Innate Immunity. Frontiers in Immunology, 2017, 8, 1968.	4.8	98
34	The Hostâ€™s Reply to Candida Biofilm. Pathogens, 2016, 5, 33.	2.8	38
35	Targeting Fibronectin To Disrupt In Vivo Candida albicans Biofilms. Antimicrobial Agents and Chemotherapy, 2016, 60, 3152-3155.	3.2	18
36	Antifungal Agents. Infectious Disease Clinics of North America, 2016, 30, 51-83.	5.1	264

#	Article	IF	Citations
37	The Extracellular Matrix of Candida albicans Biofilms Impairs Formation of Neutrophil Extracellular Traps. PLoS Pathogens, 2016, 12, e1005884.	4.7	105
38	Fungal Biofilms: <i>In Vivo</i> Models for Discovery of Anti-Biofilm Drugs. Microbiology Spectrum, 2015, 3, .	3.0	49
39	Fungal Biofilms:In VivoModels for Discovery of Anti-Biofilm Drugs. , 2015, , 33-49.		3
40	An expanded regulatory network temporally controls <scp><i>C</i></scp><i>andida albicans</i> biofilm formation. Molecular Microbiology, 2015, 96, 1226-1239.	2.5	140
41	Community participation in biofilm matrix assembly and function. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4092-4097.	7.1	139
42	Host Contributions to Construction of Three Device-Associated Candida albicans Biofilms. Infection and Immunity, 2015, 83, 4630-4638.	2.2	58
43	Novel Entries in a Fungal Biofilm Matrix Encyclopedia. MBio, 2014, 5, e01333-14.	4.1	234
44	Future directions for anti-biofilm therapeutics targeting<i>Candida</i>. Expert Review of Anti-Infective Therapy, 2014, 12, 375-382.	4.4	71
45	Rat Indwelling Urinary Catheter Model of Candida albicans Biofilm Infection. Infection and Immunity, 2014, 82, 4931-4940.	2.2	38
46	The Role of Biofilm Matrix in Mediating Antifungal Resistance. , 2014, , 1-14.		0
47	A Candida Biofilm-Induced Pathway for Matrix Glucan Delivery: Implications for Drug Resistance. PLoS Pathogens, 2012, 8, e1002848.	4.7	240
48	Portrait of Candida albicans Adherence Regulators. PLoS Pathogens, 2012, 8, e1002525.	4.7	201
49	A Recently Evolved Transcriptional Network Controls Biofilm Development in Candida albicans. Cell, 2012, 148, 126-138.	28.9	607
50	Comparative analysis ofCandidabiofilm quantitation assays. Medical Mycology, 2012, 50, 214-218.	0.7	69
51	Modeling of Fungal Biofilms Using a Rat Central Vein Catheter. Methods in Molecular Biology, 2012, 845, 547-556.	0.9	17
52	Identification and Characterization of Antifungal Compounds Using a Saccharomyces cerevisiae Reporter Bioassay. PLoS ONE, 2012, 7, e36021.	2.5	31
53	Optimizing a Candida Biofilm Microtiter Plate Model for Measurement of Antifungal Susceptibility by Tetrazolium Salt Assay. Journal of Clinical Microbiology, 2011, 49, 1426-1433.	3.9	127
54	Application of the systematic â€œDAmPâ€•approach to create a partially defective C. albicans mutant. Fungal Genetics and Biology, 2011, 48, 1056-1061.	2.1	13

#	Article	IF	Citations
55	Interface of Candida albicans Biofilm Matrix-Associated Drug Resistance and Cell Wall Integrity Regulation. Eukaryotic Cell, 2011, 10, 1660-1669.	3.4	139
56	Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms. PLoS Pathogens, 2011, 7, e1002257.	4.7	231
57	Calcineurin Controls Drug Tolerance, Hyphal Growth, and Virulence in Candida dubliniensis. Eukaryotic Cell, 2011, 10, 803-819.	3.4	97
58	Role of Fks1p and Matrix Glucan in <i>Candida albicans</i> Biofilm Resistance to an Echinocandin, Pyrimidine, and Polyene. Antimicrobial Agents and Chemotherapy, 2010, 54, 3505-3508.	3.2	188
59	Genetic Basis of<i>Candida</i>Biofilm Resistance Due to Drugâ€Sequestering Matrix Glucan. Journal of Infectious Diseases, 2010, 202, 171-175.	4.0	220
60	Development and Validation of an <i>In Vivo Candida albicans</i> Biofilm Denture Model. Infection and Immunity, 2010, 78, 3650-3659.	2.2	138
61	Biofilm Matrix Regulation by Candida albicans Zap1. PLoS Biology, 2009, 7, e1000133.	5.6	286
62	Time Course Global Gene Expression Analysis of an In Vivo<i>Candida</i>Biofilm. Journal of Infectious Diseases, 2009, 200, 307-313.	4.0	156
63	Review of techniques for diagnosis of catheter-related Candida biofilm infections. Current Fungal Infection Reports, 2008, 2, 237-243.	2.6	4
64	Complementary Adhesin Function in C. albicans Biofilm Formation. Current Biology, 2008, 18, 1017-1024.	3.9	293
65	Synergistic Effect of Calcineurin Inhibitors and Fluconazole against <i>Candida albicans</i> Biofilms. Antimicrobial Agents and Chemotherapy, 2008, 52, 1127-1132.	3.2	205
66	Reduced Biocide Susceptibility in <i>Candida albicans</i> Biofilms. Antimicrobial Agents and Chemotherapy, 2008, 52, 3411-3413.	3.2	61
67	Î²â€1,3 Glucan as a Test for Central Venous Catheter Biofilm Infection. Journal of Infectious Diseases, 2007, 195, 1705-1712.	4.0	85
68	Putative Role of Î²-1,3 Glucans in Candida albicans Biofilm Resistance. Antimicrobial Agents and Chemotherapy, 2007, 51, 510-520.	3.2	362
69	Candida albicans biofilm development, modeling a hostâ€“pathogen interaction. Current Opinion in Microbiology, 2006, 9, 340-345.	5.1	190
70	Function of Candida albicans Adhesin Hwp1 in Biofilm Formation. Eukaryotic Cell, 2006, 5, 1604-1610.	3.4	321
71	Impact of Antimicrobial Dosing Regimen on Evolution of Drug Resistance In Vivo: Fluconazole and Candida albicans. Antimicrobial Agents and Chemotherapy, 2006, 50, 2374-2383.	3.2	66
72	In Vivo Fluconazole Pharmacodynamics and Resistance Development in a Previously Susceptible Candida albicans Population Examined by Microbiologic and Transcriptional Profiling. Antimicrobial Agents and Chemotherapy, 2006, 50, 2384-2394.	3.2	35

#	Article	IF	Citations
73	Critical Role of Bcr1-Dependent Adhesins in C. albicans Biofilm Formation In Vitro and In Vivo. PLoS Pathogens, 2006, 2, e63.	4.7	443
74	Time Course of Microbiologic Outcome and Gene Expression in Candida albicans during and following In Vitro and In Vivo Exposure to Fluconazole. Antimicrobial Agents and Chemotherapy, 2006, 50, 1311-1319.	3.2	43
75	Imaging of the Development and Therapeutic Response of an In Vivo Fungal Catheter Biofilm. Microscopy Today, 2005, 13, 30-33.	0.3	0
76	Development and Characterization of an In Vivo Central Venous Catheter <i>Candida albicans</i> Biofilm Model. Infection and Immunity, 2004, 72, 6023-6031.	2.2	358
77	ROSA26 mice carry a modifier of Min-induced mammary and intestinal tumor development. Mammalian Genome, 2000, 11, 1058-1062.	2.2	4
78	Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use. , 0, , 343-371.		3